INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Clinical Trial ID NCT01911507

Rank	Title	Journal	Year	PubWeight™‹?›
1	Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.	Clin Cancer Res	2014	1.33
2	Refining the treatment of NSCLC according to histological and molecular subtypes.	Nat Rev Clin Oncol	2015	1.24
3	Novel agents and strategies for overcoming EGFR TKIs resistance.	Exp Hematol Oncol	2014	1.01
4	c-Met as a Target for Personalized Therapy.	Transl Oncogenomics	2015	0.92
5	Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.	BMC Cancer	2015	0.82
6	Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?	J Cancer	2016	0.79
7	Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.	Front Oncol	2016	0.79
8	The minority report: targeting the rare oncogenes in NSCLC.	Curr Treat Options Oncol	2014	0.78
9	Has MET met its match?	Ann Transl Med	2016	0.76
10	Biomarker development in MET-targeted therapy.	Oncotarget	2016	0.76